Other Events ·
XORTX outlines anticipated Health Canada Clinical Trial Application for gout drug XRx-026
XRTXXORTX Therapeutics Inc.
XORTX Therapeutics Inc. outlined its planned submission of a Clinical Trial Application (CTA) to Health Canada for the XRx-026 program, which evaluates XORLO, a proprietary formulation of oxypurinol, for treating gout. The filing supports a two-part clinical study, XRX-OXY-102, with Part One intended to accelerate data delivery in support of a planned New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The company noted that conducting the initial trial phase in Canada is expected to enhance regulatory strategy efficiency globally. Additionally, XORTX reported receiving increased inquiries from potential commercialization partners for the program but confirmed no agreements have been reached. XORTX Therapeutics Inc. operates as a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease.